Renal Carcinoma Clinical Trials

5 recruiting

Renal Carcinoma Trials at a Glance

8 actively recruiting trials for renal carcinoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Boston, Bethesda, and Baltimore. Lead sponsors running renal carcinoma studies include Dana-Farber Cancer Institute, M.D. Anderson Cancer Center, and Azienda Ospedaliera Universitaria Integrata Verona.

Browse renal carcinoma trials by phase

Treatments under study

About Renal Carcinoma Clinical Trials

Looking for clinical trials for Renal Carcinoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Renal Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Renal Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1Phase 2

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
National Cancer Institute (NCI)100 enrolled1 locationNCT05665361
Recruiting
Phase 2

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

Metastatic Renal Cell CarcinomaRenal Cell CarcinomaKidney Cancer+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins20 enrolled1 locationNCT03786796
Recruiting
Phase 2

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Renal Cell CarcinomaKidney CancerRenal Carcinoma+1 more
Dana-Farber Cancer Institute32 enrolled3 locationsNCT07397611
Recruiting
Phase 2

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

IvonescimabClear Cell Renal Carcinoma
M.D. Anderson Cancer Center40 enrolled1 locationNCT06940518
Recruiting
Early Phase 1

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Urothelial CarcinomaRenal Cell CarcinomaChromophobe Renal Cell Carcinoma+2 more
Dana-Farber Cancer Institute10 enrolled2 locationsNCT06318871
Recruiting
Phase 3

R.E.C.K vs Exparel in Robotic Nephrectomy

Pain ManagementRenal CarcinomaNephrectomy / Methods
Wake Forest University Health Sciences170 enrolled1 locationNCT07092566
Recruiting
Not Applicable

Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K)

Renal Carcinoma
Azienda Ospedaliera Universitaria Integrata Verona30 enrolled1 locationNCT06290427
Recruiting

China Adrenal Disease Registry

PheochromocytomaCongenital Adrenal HyperplasiaCushing Syndrome+5 more
Shanghai Jiao Tong University School of Medicine2,000 enrolled1 locationNCT04890444